[go: up one dir, main page]

MD4575B1 - Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin - Google Patents

Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin Download PDF

Info

Publication number
MD4575B1
MD4575B1 MDA20140072A MD20140072A MD4575B1 MD 4575 B1 MD4575 B1 MD 4575B1 MD A20140072 A MDA20140072 A MD A20140072A MD 20140072 A MD20140072 A MD 20140072A MD 4575 B1 MD4575 B1 MD 4575B1
Authority
MD
Moldova
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
formula
pyrrole compounds
Prior art date
Application number
MDA20140072A
Other languages
English (en)
Russian (ru)
Other versions
MD20140072A2 (ro
MD4575C1 (ro
Inventor
Тиран Арно Ле
Дигуарье Тьерри Ле
Жером-Бенуа Старк
Жан-Мишель ХЕНЛИН
Анна-Франсуаза ГИЙЮЗИС
Нантей Гийом Де
Оливье Женест
Имре ФЕЕШ
Янош Татаи
Миклош Ньергеш
Джеймс Эдвард Пол Дэвидсон
Джеймс Брук МЮРРЕЙ
Ай-Джен ЧЕНЬ
Дидье Дюран
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4575(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier, Vernalis (R&D) Ltd filed Critical Les Laboratoires Servier
Publication of MD20140072A2 publication Critical patent/MD20140072A2/ro
Publication of MD4575B1 publication Critical patent/MD4575B1/ro
Publication of MD4575C1 publication Critical patent/MD4575C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia se referă la compuşii cu formula (I):unde A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 şi T sunt definiţi în descrierea invenţiei.Invenţia se referă, de asemenea, la un procedeu de obţinere a compuşilor cu formula (I), la compoziţii farmaceutice care conţin un compus cu formula (I) şi la utilizarea unui compus cu formula (I) sau a unei sări de adiţie a acestuia cu un acid sau o bază acceptabilă farmaceutic în tratamentul formelor de cancer, bolilor autoimune şi bolilor sistemului imunitar.
MDA20140072A 2013-07-23 2014-07-15 Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin MD4575C1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357258A FR3008975A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number Publication Date
MD20140072A2 MD20140072A2 (ro) 2015-01-31
MD4575B1 true MD4575B1 (ro) 2018-06-30
MD4575C1 MD4575C1 (ro) 2019-01-31

Family

ID=50023639

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140072A MD4575C1 (ro) 2013-07-23 2014-07-15 Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin

Country Status (48)

Country Link
US (7) US9108983B2 (ro)
EP (1) EP2829539B1 (ro)
JP (1) JP5923560B2 (ro)
KR (2) KR101712111B1 (ro)
CN (3) CN106674201A (ro)
AR (1) AR096979A1 (ro)
AU (1) AU2014203521B2 (ro)
BR (1) BR102014017950B1 (ro)
CA (1) CA2856505C (ro)
CL (1) CL2014001853A1 (ro)
CR (1) CR20140307A (ro)
CU (1) CU24315B1 (ro)
CY (1) CY1118756T1 (ro)
DK (1) DK2829539T3 (ro)
DO (1) DOP2014000154A (ro)
EA (1) EA026906B1 (ro)
ES (1) ES2620515T3 (ro)
FR (1) FR3008975A1 (ro)
GE (1) GEP201706686B (ro)
GT (1) GT201400144A (ro)
HK (1) HK1203506A1 (ro)
HR (1) HRP20170349T1 (ro)
HU (1) HUE033361T2 (ro)
IL (1) IL233343A (ro)
JO (1) JO3275B1 (ro)
LT (1) LT2829539T (ro)
MA (1) MA37206B1 (ro)
MD (1) MD4575C1 (ro)
ME (1) ME02635B (ro)
MX (1) MX348370B (ro)
MY (1) MY173259A (ro)
NI (1) NI201400079A (ro)
PE (2) PE20190653A1 (ro)
PH (1) PH12014000179A1 (ro)
PL (1) PL2829539T3 (ro)
PT (1) PT2829539T (ro)
RS (1) RS55838B1 (ro)
RU (1) RU2607788C2 (ro)
SA (1) SA114350670B1 (ro)
SG (1) SG10201403750UA (ro)
SI (1) SI2829539T1 (ro)
SV (1) SV2014004770A (ro)
TN (1) TN2014000278A1 (ro)
TW (1) TWI549948B (ro)
UA (1) UA115773C2 (ro)
UY (1) UY35639A (ro)
WO (1) WO2015011400A1 (ro)
ZA (1) ZA201405323B (ro)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI759316B (zh) 2016-07-22 2022-04-01 法商施維雅藥廠 Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP7050744B2 (ja) * 2016-07-22 2022-04-08 レ ラボラトワール セルヴィエ Ｂｃｌ－２阻害剤とｍｃｌ－１阻害剤との組み合わせ、その使用及び医薬組成物
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
FR3072679B1 (fr) * 2017-10-25 2020-10-30 Servier Lab Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2988933T3 (es) 2018-06-07 2024-11-22 Disarm Therapeutics Inc Inhibidores de SARM1
GEP20237494B (en) * 2018-10-31 2023-04-10 Servier Lab Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
UY38431A (es) * 2018-10-31 2020-05-29 Servier Lab Formulación basada en ciclodextrina de un inhibidor de bcl-2
DK3891156T3 (da) * 2018-12-06 2024-02-19 Servier Lab Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
WO2020139044A1 (ko) * 2018-12-27 2020-07-02 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 항암 활성 증진용 약학 조성물
EP3903786A4 (en) 2018-12-27 2022-09-28 Holosmedic NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THEM FOR ENHANCING ANTICANCER ACTIVITY
KR20220008307A (ko) * 2019-05-14 2022-01-20 르 라보레또레 쎄르비에르 Gly101val 돌연변이를 수반하는 bcl-2 매개 암의 치료에 사용하기 위한 bcl-2 억제제
GEP20257822B (en) 2019-05-20 2025-11-10 Servier Lab Mcl-1 inhibitor antibody-drug conjugates and methods of use
CR20230046A (es) 2020-07-31 2023-04-11 Novartis Ag Combinación de un inhibidor de bcl-2 y un agente hipometilante para tratar cánceres, usos y composiciones farmacéuticas de la misma.
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
US20240376094A2 (en) 2021-02-02 2024-11-14 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
CN113129644B (zh) * 2021-03-05 2022-03-08 中国人民解放军国防科技大学 基于球面扫描线的船舶三维特征航线提取方法
CA3214107A1 (en) * 2021-03-24 2022-09-29 Les Laboratoires Servier New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds
AU2022264993A1 (en) * 2021-04-26 2023-11-09 Sunshine Lake Pharma Co., Ltd. Preparation method for pyrrole amide compound
JP7772431B2 (ja) * 2021-12-29 2025-11-18 エイル セラピューティクス，インコーポレイテッド Ｂｃｌ－２阻害薬
CN114736156B (zh) * 2022-05-18 2024-03-19 中捷四方生物科技股份有限公司 一种白叶藤碱简化衍生物的制备方法及用途
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
PE20251072A1 (es) 2022-05-20 2025-04-10 Novartis Ag Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN115960121B (zh) * 2022-10-27 2025-09-12 南通药明康德医药科技有限公司 一种合成1-(3-氧杂丁环烷基)-1h-吡唑-4-硼酸频哪醇酯的方法
IL322700A (en) 2023-03-10 2025-10-01 Novartis Ag Antibody-drug conjugates that inhibit fennerase and methods of using them
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
AR134424A1 (es) * 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
TW202539634A (zh) 2024-04-10 2025-10-16 瑞士商諾華公司 Ｐａｎｒａｓ抑制劑及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0807632B1 (en) 1995-12-01 2002-04-17 Suntory Limited Pyrroloazepine derivatives
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP2008511548A (ja) 2004-08-20 2008-04-17 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 抗アポトーシスｂｃｌ−２ファミリーメンバーの低分子阻害剤およびその使用法
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
MX2007009782A (es) 2005-02-15 2007-08-22 Novo Nordisk As 5-aminopiridin-2-ilesteres de acido 3,4-dihidro-1h-isoquinolin-2- carboxilico.
US20080269214A1 (en) * 2005-03-04 2008-10-30 Astrazeneca Ab Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
US7706888B2 (en) 2006-07-14 2010-04-27 Med-El Elektromedizinische Geraete Gmbh Bi-planar electrode with shunting gates
WO2008008912A1 (en) 2006-07-14 2008-01-17 Genelabs Technologies, Inc. Antiviral agents
SE531110C2 (sv) 2006-07-14 2008-12-23 Vaelinge Innovation Ab Låssystem omfattande ett kombinationslås för paneler
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
BRPI0918360A8 (pt) 2008-12-19 2017-12-05 Genentech Inc Composto, composição farmacêutica e usos de um composto
US8557612B2 (en) 2009-06-26 2013-10-15 California Institute Of Technology Method for fabricating micro and nanostructures in a material
EP2714681B1 (en) * 2011-05-25 2015-06-24 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859867A1 (en) * 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
UA115773C2 (uk) 2017-12-26
CN104341395B (zh) 2017-07-04
ES2620515T3 (es) 2017-06-28
TN2014000278A1 (fr) 2015-09-30
SA114350670B1 (ar) 2016-02-09
TWI549948B (zh) 2016-09-21
RS55838B1 (sr) 2017-08-31
US11058689B2 (en) 2021-07-13
US20200261464A1 (en) 2020-08-20
MY173259A (en) 2020-01-09
JP2015028018A (ja) 2015-02-12
US20210290631A1 (en) 2021-09-23
MD20140072A2 (ro) 2015-01-31
EP2829539A1 (fr) 2015-01-28
CL2014001853A1 (es) 2015-06-26
AU2014203521B2 (en) 2018-09-27
CN106674196A (zh) 2017-05-17
US20190192528A1 (en) 2019-06-27
TW201512186A (zh) 2015-04-01
US20170202851A1 (en) 2017-07-20
US20150313907A1 (en) 2015-11-05
HK1201529A1 (en) 2015-09-04
PE20190653A1 (es) 2019-05-08
DK2829539T3 (en) 2017-04-03
ZA201405323B (en) 2015-09-30
NI201400079A (es) 2014-10-24
NZ626623A (en) 2016-01-29
US20240245699A1 (en) 2024-07-25
ME02635B (me) 2017-06-20
AU2014203521A1 (en) 2015-02-12
JO3275B1 (ar) 2018-09-16
WO2015011400A1 (fr) 2015-01-29
EA026906B1 (ru) 2017-05-31
PH12014000179B1 (en) 2016-01-18
RU2607788C2 (ru) 2017-01-10
BR102014017950A2 (pt) 2015-11-17
UY35639A (es) 2015-02-27
CU20140081A7 (es) 2016-02-29
SI2829539T1 (sl) 2017-04-26
KR101712111B1 (ko) 2017-03-03
PE20150399A1 (es) 2015-04-11
CY1118756T1 (el) 2017-07-12
HK1203506A1 (en) 2015-10-30
SV2014004770A (es) 2015-01-28
US20150031673A1 (en) 2015-01-29
DOP2014000154A (es) 2014-10-15
PL2829539T3 (pl) 2017-08-31
GEP201706686B (en) 2017-06-26
MA37206B1 (fr) 2018-09-28
MX2014008867A (es) 2015-05-28
CR20140307A (es) 2014-11-17
AR096979A1 (es) 2016-02-10
US10265323B2 (en) 2019-04-23
BR102014017950B1 (pt) 2020-05-19
IL233343A (en) 2017-06-29
KR20150011786A (ko) 2015-02-02
MX348370B (es) 2017-06-08
SG10201403750UA (en) 2015-02-27
HRP20170349T1 (hr) 2017-04-21
KR20170001695A (ko) 2017-01-04
MD4575C1 (ro) 2019-01-31
US9108983B2 (en) 2015-08-18
HUE033361T2 (hu) 2017-11-28
PT2829539T (pt) 2017-01-27
CN104341395A (zh) 2015-02-11
EP2829539B1 (fr) 2016-12-21
US10688101B2 (en) 2020-06-23
CU24315B1 (es) 2018-02-08
LT2829539T (lt) 2017-02-27
PH12014000179A1 (en) 2016-01-18
CN106674201A (zh) 2017-05-17
GT201400144A (es) 2015-11-24
RU2014130125A (ru) 2016-02-20
EA201400753A1 (ru) 2015-03-31
FR3008975A1 (fr) 2015-01-30
US9598427B2 (en) 2017-03-21
JP5923560B2 (ja) 2016-05-24
CA2856505A1 (fr) 2015-01-23
CA2856505C (fr) 2017-06-27

Similar Documents

Publication Publication Date Title
MD4575B1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
MD4516B1 (ro) Derivaţi noi de tienopirimidină, procedeu de preparare a acestora, compoziţii farmaceutice care îi conţin şi utilizările lor în calitate de agenţi proapoptotici
ZA201803705B (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
MD4490B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
MY189472A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEP20176804B (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same
PH12015501609A1 (en) Phenicol antibacterials
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
NZ716155A (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
MX364479B (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA201591105A1 (ru) ПИРИМИДО[4,5-b]ХИНОЛИН-4,5-(3H,10H)-ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TH4A Change/correction in patent specification

Free format text: CHANGE OF APPLICANT ADDRESS